Upcoming event

EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

  • Nicolas Mottet,
  • Roderick C.N. van den Bergh,
  • Erik Briers,
  • Thomas Van den Broeck,
  • Marcus G. Cumberbatch,
  • Maria De Santis,
  • Stefano Fanti,
  • Nicola Fossati,
  • Giorgio Gandaglia,
  • Silke Gillessen,
  • Nikos Grivas,
  • Jeremy Grummet,
  • Ann M. Henry,
  • Theodorus H. van der Kwast,
  • Thomas B. Lam,
  • Michael Lardas,
  • Matthew Liew,
  • Malcolm D. Mason,
  • Lisa Moris,
  • Daniela E. Oprea-Lager,
  • Henk G. van der Poel,
  • Olivier Rouvière,
  • Ivo G. Schoots,
  • Derya Tilki,
  • Thomas Wiegel,
  • Peter-Paul M. Willemse,
  • Philip Cornford

Objective

To present a summary of the 2020 version of the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Geriatric Oncology (SIOG) guidelines on screening, diagnosis, and local treatment of clinically localised prostate cancer (PCa).

Evidence acquisition

The panel performed a literature review of new data, covering the time frame between 2016 and 2020. The guidelines were updated and a strength rating for each recommendation was added based on a systematic review of the evidence.

Evidence synthesis

A risk-adapted strategy for identifying men who may develop PCa is advised, generally commencing at 50 yr of age and based on individualised life expectancy. Risk-adapted screening should be offered to men at increased risk from the age of 45 yr and to breast cancer susceptibility gene (BRCA) mutation carriers, who have been confirmed to be at risk of early and aggressive disease (mainly BRAC2), from around 40 yr of age. The use of multiparametric magnetic resonance imaging in order to avoid unnecessary biopsies is recommended. When a biopsy is performed, a combination of targeted and systematic biopsies must be offered. There is currently no place for the routine use of tissue-based biomarkers. Whilst prostate-specific membrane antigen positron emission tomography computed tomography is the most sensitive staging procedure, the lack of outcome benefit remains a major limitation. Active surveillance (AS) should always be discussed with low-risk patients, as well as with selected intermediate-risk patients with favourable International Society of Urological Pathology (ISUP) 2 lesions. Local therapies are addressed, as well as the AS journey and the management of persistent prostate-specific antigen after surgery. A strong recommendation to consider moderate hypofractionation in intermediate-risk patients is provided. Patients with cN1 PCa should be offered a local treatment combined with long-term hormonal treatment.

Conclusions

The evidence in the field of diagnosis, staging, and treatment of localised PCa is evolving rapidly. The 2020 EAU-EANM-ESTRO-ESUR-SIOG guidelines on PCa summarise the most recent findings and advice for their use in clinical practice. These PCa guidelines reflect the multidisciplinary nature of PCa management.

Tags: Guidelines